Update shared on08 Aug 2025
Despite consensus revenue growth forecasts increasing to 6.4% and future P/E declining to 26.83x, LivaNova’s analyst price target remained unchanged at $64.70.
What's in the News
- LivaNova raised full-year 2025 revenue growth guidance to 8.0-9.0% (constant currency) and 9.0-10.0% (organic).
- The company was dropped from multiple Russell growth and small-cap benchmarks and indices.
- Completion of the CORE-VNS study demonstrated substantial, durable effectiveness of VNS Therapy in reducing severe focal seizures in drug-resistant epilepsy patients, with high patient retention over three years.
- LivaNova initiated the CMS process seeking national Medicare coverage for VNS Therapy in unipolar patients with treatment-resistant depression, supported by robust data from the RECOVER study and peer-reviewed publications.
Valuation Changes
Summary of Valuation Changes for LivaNova
- The Consensus Analyst Price Target remained effectively unchanged, at $64.70.
- The Consensus Revenue Growth forecasts for LivaNova has risen from 5.8% per annum to 6.4% per annum.
- The Future P/E for LivaNova has fallen slightly from 27.99x to 26.83x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.